A phase II multicenter trial with Rivaroxaban in the treatment of livedoid vasculopathy assessing the pain on a visual analog scale (VAS) - Riliva
Latest Information Update: 27 Feb 2020
Price :
$35 *
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Vascular disorders; Vasculitis
- Focus Proof of concept; Therapeutic Use
- Acronyms Riliva
- 11 Oct 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
- 24 Jan 2013 New trial record